Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Upgraded by ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a sell rating to a hold rating in a report released on Tuesday morning, ValuEngine reports.

TEVA has been the subject of a number of other research reports. BMO Capital Markets decreased their price target on shares of Teva Pharmaceutical Industries from $11.00 to $9.00 and set a market perform rating for the company in a research note on Friday, August 9th. Argus upgraded shares of Teva Pharmaceutical Industries from a hold rating to a buy rating and set a $12.00 price target for the company in a research note on Friday, July 5th. Royal Bank of Canada reiterated a hold rating and issued a $10.00 price target on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 8th. Bank of America downgraded shares of Teva Pharmaceutical Industries from a buy rating to an underperform rating and decreased their price target for the stock from $19.00 to $9.00 in a research note on Thursday, May 30th. Finally, Sanford C. Bernstein decreased their price target on shares of Teva Pharmaceutical Industries from $17.00 to $11.00 and set a market perform rating for the company in a research note on Tuesday, June 18th. They noted that the move was a valuation call. Six analysts have rated the stock with a sell rating, sixteen have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has an average rating of Hold and an average price target of $12.80.

Shares of TEVA stock opened at $7.94 on Tuesday. The company has a debt-to-equity ratio of 1.73, a quick ratio of 0.62 and a current ratio of 0.96. The stock has a market capitalization of $8.67 billion, a P/E ratio of 2.84, a price-to-earnings-growth ratio of 0.85 and a beta of 1.68. The company has a 50 day moving average price of $7.21 and a 200 day moving average price of $11.21. Teva Pharmaceutical Industries has a fifty-two week low of $6.07 and a fifty-two week high of $25.13.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The firm had revenue of $4.34 billion during the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter in the previous year, the business posted $0.78 earnings per share. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. On average, research analysts forecast that Teva Pharmaceutical Industries will post 2.25 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. Renaissance Technologies LLC lifted its position in shares of Teva Pharmaceutical Industries by 272.6% during the 2nd quarter. Renaissance Technologies LLC now owns 9,786,063 shares of the company’s stock worth $90,325,000 after buying an additional 7,159,900 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Teva Pharmaceutical Industries by 20.0% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 9,553,328 shares of the company’s stock worth $88,177,000 after buying an additional 1,593,139 shares during the last quarter. Northern Trust Corp lifted its position in shares of Teva Pharmaceutical Industries by 12.5% during the 2nd quarter. Northern Trust Corp now owns 7,610,010 shares of the company’s stock worth $70,239,000 after buying an additional 846,650 shares during the last quarter. Camber Capital Management LP lifted its position in shares of Teva Pharmaceutical Industries by 85.7% during the 2nd quarter. Camber Capital Management LP now owns 6,500,000 shares of the company’s stock worth $59,995,000 after buying an additional 3,000,000 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 0.5% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 5,348,213 shares of the company’s stock worth $49,364,000 after buying an additional 26,600 shares during the last quarter. Institutional investors and hedge funds own 57.85% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Balanced Fund

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.